These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 38728882)
1. Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia. Cui Y; Li Y; Ji J; Hu N; Min K; Ying W; Fan L; Hong M; Li J; Sun Z; Qu X Int Immunopharmacol; 2024 Jun; 134():112212. PubMed ID: 38728882 [TBL] [Abstract][Full Text] [Related]
4. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
6. Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia. Zhang W; Yang B; Weng L; Li J; Bai J; Wang T; Wang J; Ye J; Jing H; Jiao Y; Chen X; Liu H; Zeng YX Aging (Albany NY); 2020 Nov; 12(24):25337-25355. PubMed ID: 33226961 [TBL] [Abstract][Full Text] [Related]
7. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia]. Tsubaki M Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658 [TBL] [Abstract][Full Text] [Related]
8. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063 [TBL] [Abstract][Full Text] [Related]
9. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]
10. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109 [TBL] [Abstract][Full Text] [Related]
11. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis. Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia. Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
15. LncRNA OIP5-AS1 Promotes the Autophagy-Related Imatinib Resistance in Chronic Myeloid Leukemia Cells by Regulating miR-30e-5p/ATG12 Axis. Dai H; Wang J; Huang Z; Zhang H; Wang X; Li Q; Feng W Technol Cancer Res Treat; 2021; 20():15330338211052150. PubMed ID: 34723728 [No Abstract] [Full Text] [Related]
16. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192 [TBL] [Abstract][Full Text] [Related]
17. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway. Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520 [TBL] [Abstract][Full Text] [Related]